HC Wainwright Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price

Revolution Medicines (NASDAQ:RVMD) had its price objective lifted by HC Wainwright from $280.00 to $350.00 in a research report report published on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Other analysts also recently issued research reports about the stock. Piper Sandler increased their target price on shares of Revolution Medicines from $210.00 to $222.00 and gave the stock an “overweight” rating in a research report on Thursday. Raymond James Financial reaffirmed a “strong-buy” rating and set a $248.00 price target on shares of Revolution Medicines in a research report on Thursday, August 27th. Wolfe Research reaffirmed an “outperform” rating and set a $220.00 price target on shares of Revolution Medicines in a research report on Monday, August 10th. Truist Financial reiterated a “buy” rating and set a $261.00 price objective (up from $241.00) on shares of Revolution Medicines in a research note on Thursday. Finally, Morgan Stanley began coverage on shares of Revolution Medicines in a research report on Thursday, September 10th. They issued an “overweight” rating and a $255.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Revolution Medicines currently has a consensus rating of “Moderate Buy” and a consensus target price of $263.15.

Revolution Medicines Trading Up 8.2%

RVMD stock traded up $14.63 during trading on Friday, reaching $192.28. 4,496,326 shares of the stock traded hands, compared to its average volume of 1,940,895. The business’s 50 day moving average price is $196.88 and its 200-day moving average price is $157.56. Revolution Medicines has a 52-week low of $58.91 and a 52-week high of $224.31. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. The firm has a market capitalization of $41.21 billion, a PE ratio of -21.11 and a beta of 1.44.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($1.90) EPS for the quarter, topping analysts’ consensus estimates of ($2.35) by $0.45. The firm had revenue of $197.56 million during the quarter, compared to analysts’ expectations of $25.58 million. During the same quarter last year, the business earned ($1.61) earnings per share. As a group, sell-side analysts forecast that Revolution Medicines will post -8.94 earnings per share for the current year.

Insider Buying and Selling at Revolution Medicines

In related news, insider Mark Goldsmith sold 13,988 shares of Revolution Medicines stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total transaction of $2,786,969.12. Following the sale, the insider owned 253,342 shares of the company’s stock, valued at $50,475,860.08. The trade was a 5.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Margaret Horn sold 4,967 shares of the business’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $989,625.08. Following the completion of the transaction, the chief operating officer owned 149,680 shares in the company, valued at $29,822,243.20. This represents a 3.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 290,991 shares of company stock worth $59,422,765. 7.60% of the stock is currently owned by insiders.

Institutional Trading of Revolution Medicines

A number of hedge funds and other institutional investors have recently modified their holdings of RVMD. Alphabet Inc. purchased a new position in Revolution Medicines in the second quarter valued at about $551,843,000. Assenagon Asset Management S.A. increased its holdings in Revolution Medicines by 987.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company’s stock worth $447,710,000 after purchasing an additional 1,980,699 shares during the last quarter. Bank of America Corp DE purchased a new stake in Revolution Medicines during the 2nd quarter worth approximately $184,267,000. Deutsche Bank AG acquired a new position in shares of Revolution Medicines in the 2nd quarter valued at approximately $166,308,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Revolution Medicines in the 2nd quarter valued at approximately $112,566,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Strong early Rasonque sales: Revolution Medicines reported $197.6 million in third-quarter revenue, beating estimates, with Rasonque generating that amount in just five weeks after its U.S. launch. The company said more than 5,000 patients had been treated. The quarterly loss per share also came in narrower than analysts expected. Zacks article on Q3 results and Rasonque uptake
• Positive Sentiment: Analyst targets moved higher: HC Wainwright raised its target to $350 and maintained a Buy rating. RBC lifted its target to $321 with an Outperform rating; Guggenheim, Truist and TD Cowen also raised targets and retained positive ratings. These revisions signal optimism about the drug’s commercial potential and pipeline. HC Wainwright recommendations RBC target increase
• Neutral Sentiment: Long-term opportunity, but expectations are high: Rasonque’s clinical results and potential expansion into other solid tumors support the pipeline outlook. However, commentary noted that RVMD’s roughly $40 billion valuation already reflects substantial expectations, making sustained launch growth and upcoming clinical results important. Seeking Alpha analysis of Q3 results
• Negative Sentiment: Some long-range forecasts were cut: Brookline Capital Markets lowered its FY2029 EPS estimate to $8.49 from $8.94 and its FY2030 estimate to $17.41 from $18.15, though it kept a Buy rating and a $318 target.

About Revolution Medicines

Revolution Medicines, Inc is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers.

The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.